
Sign up to save your podcasts
Or


An AHA review: the OPTION, SUMMIT, VANISH 2, SARAH, and CLEAR trials are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. OPTION Trial
For AF, LAA Rivals Anticoagulants After Ablation
https://www.medscape.com/viewarticle/af-laa-rivals-anticoagulants-after-ablation-2024a1000l7n
4 Reasons to Question Percutaneous Left Atrial Appendage Closure After AF Ablation
https://www.medscape.com/viewarticle/4-reasons-question-percutaneous-left-atrial-appendage-2024a1000l0u
II. SUMMIT Trial
Tirzepatide Reduces Heart Failure Events in HFpEF With Obesity
https://www.medscape.com/viewarticle/tirzepatide-reduces-heart-failure-events-hfpef-obesity-2024a1000kx5
III. VANISH Trial
New Trial Result Pushes Past Antiarrhythmic Therapy After MI
https://www.medscape.com/viewarticle/new-trial-result-pushes-past-antiarrhythmic-therapy-after-mi-2024a1000l08
IV. Cardioprotection
Common Heart Failure Drugs Ease Heart Damage During Chemo https://www.medscape.com/viewarticle/common-heart-failure-drugs-ease-heart-damage-during-chemo-2024a1000l14
V. CLEAR trial
Spironolactone Shows Mixed Results in Acute MI
https://www.medscape.com/viewarticle/spironolactone-shows-mixed-results-acute-mi-2024a1000l41
Routine Colchicine or MRA Post-MI: No CLEAR Benefit
https://www.medscape.com/viewarticle/routine-colchicine-or-mra-post-mi-no-clear-benefit-2024a1000la2
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
By Medscape4.9
861861 ratings
An AHA review: the OPTION, SUMMIT, VANISH 2, SARAH, and CLEAR trials are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. OPTION Trial
For AF, LAA Rivals Anticoagulants After Ablation
https://www.medscape.com/viewarticle/af-laa-rivals-anticoagulants-after-ablation-2024a1000l7n
4 Reasons to Question Percutaneous Left Atrial Appendage Closure After AF Ablation
https://www.medscape.com/viewarticle/4-reasons-question-percutaneous-left-atrial-appendage-2024a1000l0u
II. SUMMIT Trial
Tirzepatide Reduces Heart Failure Events in HFpEF With Obesity
https://www.medscape.com/viewarticle/tirzepatide-reduces-heart-failure-events-hfpef-obesity-2024a1000kx5
III. VANISH Trial
New Trial Result Pushes Past Antiarrhythmic Therapy After MI
https://www.medscape.com/viewarticle/new-trial-result-pushes-past-antiarrhythmic-therapy-after-mi-2024a1000l08
IV. Cardioprotection
Common Heart Failure Drugs Ease Heart Damage During Chemo https://www.medscape.com/viewarticle/common-heart-failure-drugs-ease-heart-damage-during-chemo-2024a1000l14
V. CLEAR trial
Spironolactone Shows Mixed Results in Acute MI
https://www.medscape.com/viewarticle/spironolactone-shows-mixed-results-acute-mi-2024a1000l41
Routine Colchicine or MRA Post-MI: No CLEAR Benefit
https://www.medscape.com/viewarticle/routine-colchicine-or-mra-post-mi-no-clear-benefit-2024a1000la2
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]

320 Listeners

545 Listeners

501 Listeners

166 Listeners

40 Listeners

13 Listeners

33 Listeners

16 Listeners

3,371 Listeners

138 Listeners

1,142 Listeners

62 Listeners

40 Listeners

367 Listeners

17 Listeners

61 Listeners

26 Listeners

9 Listeners

426 Listeners

34 Listeners